It was originally developed by Metabolic Pharmaceuticals in Australia during the late 1990s as a potential **anti-obesity peptide** that could stimulate fat loss without the growth-promoting or diabetogenic effects of full-length growth hormone
Consumers should not assume that every product marketed in the BPC category has an identical formulation, manufacturing process, impurity profile, stability profile, or delivery behavior
Researchers should compare formula, molecular-weight context, batch number and COA together
Boost your energy
Research shows enhanced granulation tissue formation, improved re-epithelialization, increased collagen deposition, and superior dermal remodeling through VEGF pathway activation
Explore our full catalog of research peptides or read our related guide: What is TB-500 Used for in Research